Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy

Overview of attention for article published in Frontiers in oncology, September 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,807 followers.

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy: Background Atezolizumab was first shown to significantly improve… #oncology https://t.co/ggBVrjqgeI https

05 Sep 2022

Reply Repost Favourite

New research: Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy: Background Atezolizumab was first shown to significantly improve… https://t.co/nMd7E2xsOo

05 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.